AHAnthony Harnden

Anthony Harnden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anthony Harnden has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long COVID in Children and Young after Infection or Reinfection with the Omicron Variant: A Prospective Observational Study

    by Snehal M. Pinto Pereira, Anna Mensah, Manjula D. Nugawela, Terence Stephenson, Shamez N. Ladhani, Emma Dalrymple, Jake Dudley, Kelsey McOwat, Ruth Simmons, Isobel Heyman, et al.


  • Top Cited Papers

    Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex

    by Martina Patone, Xue W. Mei, Lahiru Handunnetthi, Sharon Dixon, Francesco Zaccardi, Manu Shankar-Hari, Peter Watkinson, Kamlesh Khunti, Anthony Harnden, Carol A.C. Coupland, et al.

    Background: Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain. Methods: A self-controlled case series study of people ages 13 years or older vaccinated for COVID-19 in England between December 1, 2020, and December 15, 2021, evaluated the association between vaccination and myocarditis, stratified by age and sex. The incidence rate ratio and excess number of hospital admissions or deaths from myocarditis per million people were estimated for the 1 to 28 days after sequential doses of adenovirus (ChAdOx1) or mRNA-based (BNT162b2, mRNA-1273) vaccines, or after a positive SARS-CoV-2 test. Results: In 42 842 345 people receiving at least 1 dose of vaccine, 21 242 629 received 3 doses, and 5 934 153 had SARS-CoV-2 infection before or after vaccination. Myocarditis occurred in 2861 (0.007%) people, with 617 events 1 to 28 days after vaccination. Risk of myocarditis was increased in the 1 to 28 days after a first dose of ChAdOx1 (incidence rate ratio, 1.33 [95% CI, 1.09–1.62]) and a first, second, and booster dose of BNT162b2 (1.52 [95% CI, 1.24–1.85]; 1.57 [95% CI, 1.28–1.92], and 1.72 [95% CI, 1.33–2.22], respectively) but was lower than the risks after a positive SARS-CoV-2 test before or after vaccination (11.14 [95% CI, 8.64–14.36] and 5.97 [95% CI, 4.54–7.87], respectively). The risk of myocarditis was higher 1 to 28 days after a second dose of mRNA-1273 (11.76 [95% CI, 7.25–19.08]) and persisted after a booster dose (2.64 [95% CI, 1.25–5.58]). Associations were stronger in men younger than 40 years for all vaccines. In men younger than 40 years old, the number of excess myocarditis events per million people was higher after a second dose of mRNA-1273 than after a positive SARS-CoV-2 test (97 [95% CI, 91–99] versus 16 [95% CI, 12–18]). In women younger than 40 years, the number of excess events per million was similar after a second dose of mRNA-1273 and a positive test (7 [95% CI, 1–9] versus 8 [95% CI, 6–8]). Conclusions: Overall, the risk of myocarditis is greater after SARS-CoV-2 infection than after COVID-19 vaccination and remains modest after sequential doses including a booster dose of BNT162b2 mRNA vaccine. However, the risk of myocarditis after vaccination is higher in younger men, particularly after a second dose of the mRNA-1273 vaccine.


  • Open Access

    Long COVID - the physical and mental health of children and non-hospitalised young people 3 months after SARS-CoV-2 infection; a national matched cohort study (The CLoCk) Study.

    by Terence Stephenson, Snehal Pinto Pereira, Roz Shafran, Bianca De Stavola, Natalia Rojas, Kelsey McOwat, Ruth Simmons, Maria Zavala, Lauren O’mAhoney, Trudie Chalder, et al.

    Introduction: We describe post-COVID symptomatology in a national sample of 11-17-year-old children and young people (CYP) with PCR-confirmed SARS-CoV-2 infection compared to test-negative controls.Methods and analysis: A cohort study of test-positive (n=3,065) and age-, sex- and geographically-matched test-negative CYP (n=3,739) completed detailed questionnaires 3 months post-test.Results: At PCR-testing, 35.4% of test-positives and 8.3% of test-negatives had any symptoms whilst 30.6% and 6.2%, respectively, had 3+ symptoms. At 3 months post-testing, 66.5% of test-positives and 53.3% of test-negatives had any symptoms, whilst 30.3% and 16.2%, respectively, had 3+ symptoms. Latent class analysis identified two classes, characterised by “few” or “multiple” symptoms. This latter class was more frequent among test-positives, females, older CYP and those with worse pre-test physical and mental health.Discussion: Test-positive CYP had a similar symptom profile to test-negative CYP but with higher prevalence of single and, particularly, multiple symptoms at PCR-testing and 3 months later.


  • Open Access

    Lessons from the United Kingdom’s COVID‐19 vaccination strategy

    by Anthony Harnden, Andrew Earnshaw

    Click on the article title to read more.


  • Open Access

    Can oral corticosteroids reduce the severity or duration of an acute cough, and the associated National Health Service and societal costs, in adults presenting to primary care? Study protocol for a randomised controlled trial

    by Harriet E Downing, on behalf of the OSAC trial team, Fran Carroll, Sara T Brookes, Sandra Hollinghurst, David Timmins, Elizabeth Orton, Kay Wang, Denise Kendrick, Paul Little, et al.

    Acute lower respiratory tract infection (LRTI) is one of the most common conditions managed internationally and is costly to health services and patients. Despite good evidence that antibiotics are not effective for improving the symptoms of uncomplicated LRTI, they are widely prescribed, contributing to antimicrobial resistance. Many of the symptoms observed in LRTI are mediated by inflammatory processes also observed in exacerbations of asthma, for which there is strong evidence of corticosteroid effectiveness. The primary aim of the OSAC (Oral Steroids for Acute Cough) Trial is to determine whether oral prednisolone (40 mg daily for 5 days) can reduce the duration of moderately bad (or worse) cough and the severity of all its associated symptoms on days 2 to 4 post-randomisation (day 1 is trial entry) by at least 20% in adults ≥18 years with acute LRTI presenting to primary care. OSAC is a two-arm, multi-centre, placebo-controlled, randomised superiority trial. The target sample size is 436 patients, which allows for a 20% dropout rate. Patients will be recruited from primary care sites (General Practitioner surgeries) across England and followed up until symptom resolution. The two primary clinical outcomes are the duration of moderately bad (or worse) cough, and the severity of all its associated symptoms on days 2 to 4 post-randomisation. Secondary outcomes include: antibiotic consumption; symptom burden; adverse events; participant satisfaction with treatment and intention to consult for future similar illnesses. A parallel economic evaluation will investigate the cost-effectiveness of the intervention. Results from the OSAC trial will increase knowledge regarding the clinical and cost-effectiveness of corticosteroids for LRTI, and will establish the potential of a new treatment option that could substantially improve patient health. We have chosen a relatively high ‘efficacy dose’ as this will enable us to decide on the potential for further research into lower dose oral and/or inhaled corticosteroids. This trial will also contribute to a growing body of research investigating the natural course of this very common illness, as well as the effects of steroids on the undesirable inflammatory symptoms associated with infection. Current Controlled Trials ISRCTN57309858 (31 January 2013).


  • Kawasaki disease

    by Anthony Harnden, Robert Tulloh, David Burgner

    A 2 year old boy was brought to see the general practitioner by his parents because of a four day history of fever. His parents noticed a rash and slightly “bloodshot” eyes the day before. The GP diagnosed a viral illness, offered reassurance, but gave good safety netting advice. The boy re-presented to his GP three days later, still intermittently febrile, irritable, and with an angry looking widespread morbilliform rash and a sore mouth. Kawasaki disease was suspected, and he was admitted to hospital where he received prompt treatment with intravenous immunoglobulin and high dose aspirin. An echocardiogram, performed during admission was normal, as were those during follow-up.


  • Open Access

    General practitioners’ views on quality markers for children in UK primary care: a qualitative study

    by Peter J Gill, Jenny Hislop, David Mant, Anthony Harnden

    Children make up about 20% of the UK population and caring for them is an important part of a general practitioner’s (GP’s) workload. However, the UK Quality Outcomes Framework (pay-for-performance system) largely ignores children – less than 3% of the quality markers relate to them. As no previous research has investigated whether GPs would support or oppose the introduction of child-specific quality markers, we sought their views on this important question.


  • Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)

    by Kay Wang, Matthew Shun-Shin, Peter Gill, Rafael Perera, Anthony Harnden

    During epidemics, influenza attack rates in children may exceed 40%. Options for prevention and treatment currently include the neuraminidase inhibitors zanamivir and oseltamivir. Laninamivir octanoate, the prodrug of laninamivir, is currently being developed. To assess the efficacy, safety and tolerability of neuraminidase inhibitors in the treatment and prevention of influenza in children. For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 1) which includes the Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to January week 2, 2011) and EMBASE (January 2010 to January 2011). Double‐blind, randomised controlled trials (RCTs) comparing neuraminidase inhibitors with placebo or other antiviral drugs in children aged up to and including 12 years. We also included safety and tolerability data from other types of studies. Four review authors selected studies, assessed study quality and extracted data for the current and previous versions of this review. We analysed data separately for oseltamivir versus placebo, zanamivir versus placebo and laninamivir octanoate versus oseltamivir. Six treatment trials involving 1906 children with clinical influenza and 450 children with influenza diagnosed on rapid near‐patient influenza testing were included. Of these 2356 children, 1255 had laboratory‐confirmed influenza. Three prophylaxis trials involving 863 children exposed to influenza were also included. In children with laboratory‐confirmed influenza oseltamivir reduced median duration of illness by 36 hours (26%, P < 0.001). One trial of oseltamivir in children with asthma who had laboratory‐confirmed influenza showed only a small reduction in illness duration (10.4 hours, 8%), which was not statistically significant (P = 0.542). Laninamivir octanoate 20 mg reduced symptom duration by 2.8 days (60%, P < 0.001) in children with oseltamivir‐resistant influenza A/H1N1. Zanamivir reduced median duration of illness by 1.3 days (24%, P < 0.001). Oseltamivir significantly reduced acute otitis media in children aged one to five years with laboratory‐confirmed influenza (risk difference (RD) ‐0.14, 95% confidence interval (CI) ‐0.24 to ‐0.04). Prophylaxis with either zanamivir or oseltamivir was associated with an 8% absolute reduction in developing influenza after the introduction of a case into a household (RD ‐0.08, 95% CI ‐0.12 to ‐0.05, P < 0.001). The adverse event profile of zanamivir was no worse than placebo but vomiting was more commonly associated with oseltamivir (number needed to harm = 17, 95% CI 10 to 34). The adverse event profiles of laninamivir octanoate and oseltamivir were similar. Oseltamivir and zanamivir appear to have modest benefit in reducing duration of illness in children with influenza. However, our analysis was limited by small sample sizes and an inability to pool data from different studies. In addition, the inclusion of data from published trials only may have resulted in significant publication bias. Based on published trial data, oseltamivir reduces the incidence of acute otitis media in children aged one to five years but is associated with a significantly increased risk of vomiting. One study demonstrated that laninamivir octanoate was more effective than oseltamivir in shortening duration of illness in children with oseltamivir‐resistant influenza A/H1N1. The benefit of oseltamivir and zanamivir in preventing the transmission of influenza in households is modest and based on weak evidence. However, the clinical efficacy of neuraminidase inhibitors in 'at risk' children is still uncertain. Larger high‐quality trials are needed with sufficient power to determine the efficacy of neuraminidase inhibitors in preventing serious complications of influenza (such as pneumonia or hospital admission), particularly in 'at risk' groups. Inhibiteurs de la neuraminidase dans la prévention et le traitement de la grippe chez les enfants Lors de périodes épidémiques, les taux d'attaque de la grippe chez les enfants peuvent dépasser 40 %. Les options de prévention et de traitement sont actuellement les inhibiteurs de la neuraminidase, le zanamivir et l'oseltamivir. Le laninamivir octanoate, promédicament du laninamivir, est actuellement en cours de développement. Évaluer l'efficacité, l'innocuité et la tolérabilité des inhibiteurs de la neuraminidase pour le traitement et la prévention de la grippe chez les enfants. Pour cette mise à jour, nous avons effectué des recherches dans le registre Cochrane des essais contrôlés (CENTRAL) (The Cochrane Library 2011, numéro 1), qui contient le registre spécialisé du groupe Cochrane sur les infections respiratoires aiguës, MEDLINE (1966 à la semaine 2 de janvier 2011) et EMBASE (janvier 2010 à janvier 2011). Des essais contrôlés randomisés (ECR), en double aveugle, comparant les inhibiteurs de la neuraminidase à un placebo ou d'autres médicaments antiviraux chez les enfants âgés de 12 ans au maximum. Nous avons également inclus des données relatives à l'innocuité et la tolérabilité issues d'autres types d'études. Quatre auteurs de la revue ont sélectionné des études, évalué leur qualité et extrait des données pour les versions actuelles et précédentes de cette revue. Nous avons analysé séparément les données comparant l'oseltamivir à un placebo, le zanamivir à un placebo et le laninamivir octanoate à l'oseltamivir. Six essais de traitement étaient inclus avec un total de 1 906 enfants souffrant d'une grippe clinique et 450 enfants souffrant d'une grippe diagnostiquée à l'aide d'un test grippal rapide réalisé au chevet du patient. Sur ces 2 356 enfants, 1 255 présentaient des cas de grippe confirmés en laboratoire. Trois essais portant sur la prophylaxie et incluant 863 enfants exposés à la grippe étaient également inclus. Chez les enfants dont les cas de grippe étaient confirmés en laboratoire, l'oseltamivir a réduit la durée moyenne de la maladie de 36 heures (26 %, P < 0,001). Un essai portant sur la prise d'oseltamivir chez les enfants asthmatiques, présentant des cas de grippe confirmés en laboratoire, ne révélait qu'une baisse minime de la durée de la maladie (10,4 heures, 8 %), ce qui n'était pas statistiquement significatif (P = 0,542). Une dose de 20 mg de laninamivir octanoate a réduit la durée des symptômes de 2,8 jours (60 %, P < 0,001) chez les enfants souffrant de la grippe A/H1N1 résistante à l'oseltamivir. Le zanamivir a réduit la durée moyenne de la maladie de 1,3 jour (24 %, P < 0,001). L'oseltamivir a sensiblement réduit les cas d'otites aiguës chez les enfants âgés de 1 à 5 ans et souffrant de cas de grippe confirmés en laboratoire (différence de risques (DR) ‐ 0,14, intervalle de confiance (IC) à 95 % ‐ 0,24 à ‐ 0,04). La prophylaxie avec le zanamivir ou l'oseltamivir était liée à une baisse absolue de 8 % du développement de la grippe après avoir introduit un cas dans un foyer (DR ‐ 0,08, IC à 95 % ‐ 0,12 à ‐ 0,05, P < 0,01). Le profil des événements indésirables du zanamivir n'était pas plus mauvais que celui d'un placebo, mais les cas de vomissement étaient plus couramment associés à l'oseltamivir (nombre de patients pour observer un évènement négatif = 17, IC à 95 % 10 à 34). Les profils des événements indésirables du laninamivir octanoate et de l'oseltamivir étaient similaires. L'oseltamivir et le zanamivir semblent avoir des effets bénéfiques modestes sur la baisse de la durée de la maladie chez les enfants atteints de grippe. Toutefois, notre analyse était limitée en raison de la taille réduite des échantillons et de l'impossibilité de regrouper les données issues de différentes études. L'oseltamivir réduit l'incidence des cas d'otites moyennes aiguës chez les enfants âgés de 1 à 5 ans, mais il est lié à une aggravation des cas de vomissement. Une étude a démontré que le laninamivir octanoate était plus efficace que l'oseltamivir en termes de raccourcissement de la durée de la maladie chez les enfants souffrant de la grippe A/H1N1 résistante à l'oseltamivir. Les avantages de l'oseltamivir et du zanamivir en termes de prévention de la transmission de la grippe dans les foyers sont modestes et reposent sur des preuves insuffisantes. Toutefois, l'efficacité clinique des inhibiteurs de la neuraminidase chez les enfants « à risque » reste incertaine. Des essais à plus grande échelle et de qualité supérieure sont nécessaires avec une puissance statistique suffisante afin de déterminer l'efficacité des inhibiteurs de la neuraminidase dans le cadre de la prévention de complications graves de la grippe (comme la pneumonie ou une hospitalisation), plus particulièrement chez les groupes « à risque ».


  • Neuraminidase inhibitors for preventing and treating influenza in children

    by Kay Wang, Matthew Shun-Shin, Peter Gill, Rafael Perera, Anthony Harnden

    During epidemics, influenza attack rates in children may exceed 40%. Options for prevention and treatment currently include the neuraminidase inhibitors zanamivir and oseltamivir. Laninamivir octanoate, the prodrug of laninamivir, is currently being developed. To assess the efficacy, safety and tolerability of neuraminidase inhibitors in the treatment and prevention of influenza in children. For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 1) which includes the Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to January week 2, 2011) and EMBASE (January 2010 to January 2011). Double‐blind, randomised controlled trials (RCTs) comparing neuraminidase inhibitors with placebo or other antiviral drugs in children aged up to and including 12 years. We also included safety and tolerability data from other types of studies. Four review authors selected studies, assessed study quality and extracted data for the current and previous versions of this review. We analysed data separately for oseltamivir versus placebo, zanamivir versus placebo and laninamivir octanoate versus oseltamivir. Six treatment trials involving 1906 children with clinical influenza and 450 children with influenza diagnosed on rapid near‐patient influenza testing were included. Of these 2356 children, 1255 had laboratory‐confirmed influenza. Three prophylaxis trials involving 863 children exposed to influenza were also included. In children with laboratory‐confirmed influenza oseltamivir reduced median duration of illness by 36 hours (26%, P < 0.001). One trial of oseltamivir in children with asthma who had laboratory‐confirmed influenza showed only a small reduction in illness duration (10.4 hours, 8%), which was not statistically significant (P = 0.542). Laninamivir octanoate 20 mg reduced symptom duration by 2.8 days (60%, P < 0.001) in children with oseltamivir‐resistant influenza A/H1N1. Zanamivir reduced median duration of illness by 1.3 days (24%, P < 0.001). Oseltamivir significantly reduced acute otitis media in children aged one to five years with laboratory‐confirmed influenza (risk difference (RD) ‐0.14, 95% confidence interval (CI) ‐0.24 to ‐0.04). Prophylaxis with either zanamivir or oseltamivir was associated with an 8% absolute reduction in developing influenza after the introduction of a case into a household (RD ‐0.08, 95% CI ‐0.12 to ‐0.05, P < 0.001). The adverse event profile of zanamivir was no worse than placebo but vomiting was more commonly associated with oseltamivir (number needed to harm = 17, 95% CI 10 to 34). The adverse event profiles of laninamivir octanoate and oseltamivir were similar. Oseltamivir and zanamivir appear to have modest benefit in reducing duration of illness in children with influenza. However, our analysis was limited by small sample sizes and an inability to pool data from different studies. Oseltamivir reduces the incidence of acute otitis media in children aged one to five years but is associated with a significantly increased risk of vomiting. One study demonstrated that laninamivir octanoate was more effective than oseltamivir in shortening duration of illness in children with oseltamivir‐resistant influenza A/H1N1. The benefit of oseltamivir and zanamivir in preventing the transmission of influenza in households is modest and based on weak evidence. However, the clinical efficacy of neuraminidase inhibitors in 'at risk' children is still uncertain. Larger high‐quality trials are needed with sufficient power to determine the efficacy of neuraminidase inhibitors in preventing serious complications of influenza (such as pneumonia or hospital admission), particularly in 'at risk' groups.